InnoMed Technologies, Inc. Signs 800th Sleep Disorder Facility for Nasal Aire Interface

Tuesday, May 14, 2002

ABC News (abcnews.com)

InnoMed Technologies, Inc., announced today that in just over three months the company has signed agreements with 800 sleep disorder treatment facilities in the United States. In addition, the company's staff has grown by 45% and its distributor sales force has increased by 18% to support its Nasal Aire(R) Interface sales since January of this year.

"The success of the Nasal Aire(R) has reached beyond the U.S. and the company is shipping devices to 10 foreign countries, has agreements with three foreign distributors, and has vastly expanded its manufacturing facilities," said InnoMed Technologies CEO R. Patrick Karem. "We are selling an enormous amount of product because acceptance of the Nasal Aire(R) Interface is nothing short of phenomenal. I have personally been approached by a number of mask users who have thrown their old masks away due to the discomfort and are very pleased with the Nasal Aire(R). Nothing has been more gratifying than receiving such positive feedback from patients."

Karem went on to state, "At this time, InnoMed's market share potential is unlimited. We have achieved all this in a very short period of time despite negative comments similar to ones made by an executive of a competitor company on May 2nd."

InnoMed Technologies' success is built by its experienced personnel, composed of top industry management, sales and technical people, as well as its Medical Advisory Board of over 170 medical doctors.

Independent clinical trials were conducted last year for the NASAL AIRE(R) Interface which showed that when patients are given a choice between using the NASAL AIRE(R) Interface or the three leading competitive masks, manufactured by Resmed, Inc. (NYSE:RMD) and Respironics (Nasdaq:RESP), and Mallinckrodt, 98% of the time the NASAL AIRE(R) Interface was chosen.

InnoMed Technologies, Inc. is a 21st Century medical technologies company. The company is poised to bring new and more effective medical products and devices to the public through a medical development and engineering team, as well as acquisitions of other medical related companies. InnoMed Technologies, Inc. has primarily been a research oriented, privately held, medical technology development company for the past four years. The company owns a full utility patent and patents pending. More information regarding InnoMed Technologies is available at http://www.innomedinc.com.

InnoMed's parent company is Mergenet Solutions, Inc., a full service technology incubator based in Boca Raton, Florida. The company also can assist private companies in their efforts to become public, as well as ancillary services, such as providing a board of directors, constructing company advisory boards, private placements, etc.

A Private Securities Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in written statements to be made) contain statements that are forward-looking, such as those relating to consummation of the transaction, anticipated future revenue of the Company's, and success of current public offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward looking statements.